Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 16 | 2020 | 156 | 1.680 |
Why?
|
| Drug Resistance, Microbial | 14 | 2013 | 70 | 0.950 |
Why?
|
| Anti-Bacterial Agents | 13 | 2022 | 1026 | 0.900 |
Why?
|
| Staphylococcus aureus | 13 | 2012 | 175 | 0.890 |
Why?
|
| Cross Infection | 18 | 2018 | 195 | 0.880 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 98 | 0.760 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2020 | 92 | 0.680 |
Why?
|
| Coagulase | 7 | 2006 | 14 | 0.580 |
Why?
|
| Meningococcal Infections | 1 | 2015 | 5 | 0.530 |
Why?
|
| Diphtheria | 1 | 2015 | 6 | 0.530 |
Why?
|
| Whooping Cough | 1 | 2015 | 8 | 0.530 |
Why?
|
| Meningococcal Vaccines | 1 | 2015 | 17 | 0.530 |
Why?
|
| Tetanus | 1 | 2015 | 11 | 0.530 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2015 | 15 | 0.530 |
Why?
|
| Domestic Violence | 1 | 2015 | 36 | 0.510 |
Why?
|
| Immunization | 1 | 2015 | 86 | 0.510 |
Why?
|
| Physician's Role | 1 | 2015 | 116 | 0.490 |
Why?
|
| Hospitals, Veterans | 3 | 2011 | 147 | 0.480 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 93 | 0.480 |
Why?
|
| Anti-Infective Agents | 6 | 2018 | 166 | 0.480 |
Why?
|
| Methicillin Resistance | 7 | 2008 | 45 | 0.480 |
Why?
|
| Societies, Medical | 3 | 2015 | 403 | 0.460 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 194 | 0.430 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 300 | 0.420 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 158 | 0.420 |
Why?
|
| Health Planning | 1 | 2011 | 23 | 0.380 |
Why?
|
| Staphylococcus | 5 | 1999 | 29 | 0.370 |
Why?
|
| Bacterial Proteins | 3 | 2012 | 245 | 0.340 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2011 | 307 | 0.340 |
Why?
|
| Bacterial Toxins | 2 | 2008 | 50 | 0.320 |
Why?
|
| Leukocidins | 1 | 2008 | 1 | 0.310 |
Why?
|
| Exotoxins | 1 | 2008 | 4 | 0.310 |
Why?
|
| Disinfectants | 3 | 2013 | 61 | 0.300 |
Why?
|
| Community-Acquired Infections | 1 | 2008 | 46 | 0.300 |
Why?
|
| Copper | 3 | 2013 | 149 | 0.290 |
Why?
|
| Fluoroquinolones | 4 | 1999 | 49 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 511 | 0.280 |
Why?
|
| Genetic Variation | 1 | 2008 | 220 | 0.280 |
Why?
|
| R Factors | 3 | 1994 | 8 | 0.250 |
Why?
|
| Ciprofloxacin | 3 | 1999 | 30 | 0.240 |
Why?
|
| Humans | 42 | 2022 | 68618 | 0.240 |
Why?
|
| DNA Topoisomerases, Type II | 3 | 1999 | 13 | 0.240 |
Why?
|
| Trimethoprim Resistance | 3 | 1994 | 4 | 0.230 |
Why?
|
| Skin Diseases, Infectious | 1 | 2003 | 16 | 0.220 |
Why?
|
| Soft Tissue Infections | 1 | 2003 | 19 | 0.220 |
Why?
|
| Fomites | 2 | 2013 | 12 | 0.220 |
Why?
|
| Necrosis | 1 | 2003 | 239 | 0.210 |
Why?
|
| Naphthyridines | 2 | 1999 | 20 | 0.210 |
Why?
|
| Scrub Typhus | 1 | 2022 | 2 | 0.210 |
Why?
|
| Dysentery, Bacillary | 2 | 1994 | 8 | 0.200 |
Why?
|
| Azithromycin | 1 | 2022 | 13 | 0.200 |
Why?
|
| Gentamicins | 6 | 1993 | 68 | 0.200 |
Why?
|
| Escherichia coli | 3 | 1994 | 368 | 0.200 |
Why?
|
| Doxycycline | 1 | 2022 | 49 | 0.200 |
Why?
|
| Shigella sonnei | 2 | 1992 | 3 | 0.190 |
Why?
|
| Intensive Care Units | 2 | 2013 | 344 | 0.190 |
Why?
|
| Conjugation, Genetic | 5 | 1994 | 7 | 0.180 |
Why?
|
| South Carolina | 6 | 2015 | 2752 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 11 | 1999 | 226 | 0.170 |
Why?
|
| Methicillin | 5 | 1990 | 11 | 0.170 |
Why?
|
| Environmental Microbiology | 2 | 2013 | 25 | 0.130 |
Why?
|
| Personnel, Hospital | 3 | 1993 | 19 | 0.130 |
Why?
|
| Editorial Policies | 1 | 2015 | 32 | 0.120 |
Why?
|
| DNA, Bacterial | 3 | 1992 | 150 | 0.120 |
Why?
|
| Disinfection | 2 | 2013 | 112 | 0.120 |
Why?
|
| Shigella dysenteriae | 1 | 1994 | 2 | 0.120 |
Why?
|
| Shigella flexneri | 1 | 1994 | 9 | 0.120 |
Why?
|
| Travel | 1 | 1994 | 38 | 0.120 |
Why?
|
| Nose | 1 | 1993 | 36 | 0.110 |
Why?
|
| Violence | 1 | 2015 | 275 | 0.110 |
Why?
|
| Tobramycin | 2 | 1991 | 38 | 0.110 |
Why?
|
| Plasmids | 6 | 1993 | 258 | 0.110 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 35 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 62 | 0.110 |
Why?
|
| Long-Term Care | 1 | 1991 | 53 | 0.090 |
Why?
|
| Hospitals | 3 | 2012 | 265 | 0.090 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2008 | 23 | 0.090 |
Why?
|
| Carrier State | 3 | 1993 | 39 | 0.090 |
Why?
|
| Bacteremia | 2 | 2006 | 155 | 0.080 |
Why?
|
| Diterpenes | 1 | 2008 | 42 | 0.080 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2008 | 64 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 137 | 0.070 |
Why?
|
| Male | 10 | 2022 | 37321 | 0.070 |
Why?
|
| Adhesins, Bacterial | 1 | 2006 | 13 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 58 | 0.070 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2006 | 14 | 0.070 |
Why?
|
| Polystyrenes | 1 | 2006 | 20 | 0.070 |
Why?
|
| Ions | 1 | 2006 | 50 | 0.070 |
Why?
|
| Female | 9 | 2022 | 38074 | 0.060 |
Why?
|
| Penicillin Resistance | 5 | 1990 | 12 | 0.060 |
Why?
|
| Quinolines | 1 | 1984 | 48 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 1984 | 55 | 0.060 |
Why?
|
| Polymers | 1 | 2006 | 244 | 0.060 |
Why?
|
| Colony Count, Microbial | 3 | 2013 | 77 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 3 | 1991 | 32 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 848 | 0.060 |
Why?
|
| Bacterial Infections | 3 | 1997 | 163 | 0.060 |
Why?
|
| Intensive Care Units, Neonatal | 4 | 1992 | 113 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1993 | 44 | 0.050 |
Why?
|
| DNA Topoisomerase IV | 2 | 1999 | 2 | 0.050 |
Why?
|
| Serratia marcescens | 2 | 1985 | 5 | 0.050 |
Why?
|
| Serotyping | 4 | 1994 | 16 | 0.050 |
Why?
|
| Disease Outbreaks | 3 | 1990 | 83 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 931 | 0.050 |
Why?
|
| Orientia tsutsugamushi | 1 | 2022 | 1 | 0.050 |
Why?
|
| Rickettsiaceae Infections | 1 | 2022 | 3 | 0.050 |
Why?
|
| Klebsiella Infections | 2 | 1996 | 13 | 0.050 |
Why?
|
| India | 1 | 2022 | 41 | 0.050 |
Why?
|
| Restriction Mapping | 2 | 1994 | 85 | 0.050 |
Why?
|
| Bacteriophage Typing | 2 | 1993 | 3 | 0.050 |
Why?
|
| Pseudomonas Infections | 3 | 1996 | 83 | 0.050 |
Why?
|
| Genetic Code | 1 | 1981 | 4 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 96 | 0.050 |
Why?
|
| United States | 3 | 2011 | 7367 | 0.050 |
Why?
|
| Base Sequence | 2 | 2001 | 1015 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2001 | 40 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 3 | 1993 | 18 | 0.050 |
Why?
|
| Genetics, Microbial | 1 | 2000 | 1 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 1980 | 33 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1980 | 59 | 0.040 |
Why?
|
| Aged | 7 | 2013 | 14862 | 0.040 |
Why?
|
| Bacteria | 4 | 2012 | 193 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 1999 | 1 | 0.040 |
Why?
|
| Oxacillin | 1 | 1999 | 4 | 0.040 |
Why?
|
| Codon | 1 | 1999 | 21 | 0.040 |
Why?
|
| Enterobacteriaceae Infections | 3 | 1985 | 25 | 0.040 |
Why?
|
| Time Factors | 4 | 2003 | 4655 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 567 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 772 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 3 | 2000 | 19 | 0.040 |
Why?
|
| Double-Blind Method | 4 | 2006 | 1738 | 0.040 |
Why?
|
| Candidiasis | 1 | 1977 | 39 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 1994 | 22 | 0.040 |
Why?
|
| Military Medicine | 1 | 1977 | 53 | 0.040 |
Why?
|
| Risk Factors | 3 | 2000 | 5731 | 0.040 |
Why?
|
| Organizational Policy | 1 | 1997 | 42 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 1993 | 649 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 1996 | 24 | 0.040 |
Why?
|
| Trimethoprim | 1 | 1976 | 8 | 0.030 |
Why?
|
| Sulfamethoxazole | 1 | 1976 | 15 | 0.030 |
Why?
|
| Infection Control | 1 | 1997 | 101 | 0.030 |
Why?
|
| Mice | 1 | 2008 | 8474 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 3 | 1996 | 133 | 0.030 |
Why?
|
| DNA Restriction Enzymes | 2 | 1993 | 49 | 0.030 |
Why?
|
| Infant | 1 | 2022 | 2891 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 3187 | 0.030 |
Why?
|
| Aminoglycosides | 2 | 1988 | 54 | 0.030 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 1994 | 9 | 0.030 |
Why?
|
| DNA Probes | 1 | 1994 | 57 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 38 | 0.030 |
Why?
|
| Bulgaria | 2 | 1992 | 2 | 0.030 |
Why?
|
| Wound Infection | 1 | 1993 | 20 | 0.030 |
Why?
|
| Vancomycin Resistance | 1 | 2013 | 18 | 0.030 |
Why?
|
| Patients' Rooms | 1 | 2013 | 15 | 0.030 |
Why?
|
| Enterococcus | 1 | 2013 | 29 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2013 | 35 | 0.030 |
Why?
|
| Mutation | 1 | 1998 | 1213 | 0.030 |
Why?
|
| Shigella boydii | 1 | 1992 | 1 | 0.030 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2012 | 15 | 0.030 |
Why?
|
| Vancomycin | 3 | 2006 | 60 | 0.030 |
Why?
|
| Middle Aged | 6 | 2013 | 21147 | 0.030 |
Why?
|
| Kanamycin Kinase | 1 | 1991 | 2 | 0.030 |
Why?
|
| RNA Probes | 1 | 1991 | 15 | 0.030 |
Why?
|
| DNA, Superhelical | 1 | 1991 | 8 | 0.030 |
Why?
|
| Phosphotransferases | 1 | 1991 | 16 | 0.020 |
Why?
|
| Isomerism | 1 | 1991 | 63 | 0.020 |
Why?
|
| Phylogeny | 1 | 2012 | 197 | 0.020 |
Why?
|
| Salmonella | 1 | 1991 | 20 | 0.020 |
Why?
|
| Phenotype | 1 | 1994 | 947 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1991 | 130 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 20881 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 7029 | 0.020 |
Why?
|
| Adult | 5 | 2013 | 21403 | 0.020 |
Why?
|
| Transfection | 1 | 1991 | 782 | 0.020 |
Why?
|
| Ampicillin Resistance | 1 | 1989 | 2 | 0.020 |
Why?
|
| Tetracycline Resistance | 1 | 1989 | 3 | 0.020 |
Why?
|
| Streptomycin | 1 | 1989 | 12 | 0.020 |
Why?
|
| Urinary Tract Infections | 2 | 1981 | 71 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1603 | 0.020 |
Why?
|
| Enterobacter | 2 | 1985 | 3 | 0.020 |
Why?
|
| Sulfonamides | 1 | 1989 | 141 | 0.020 |
Why?
|
| Patient Isolation | 2 | 1997 | 35 | 0.020 |
Why?
|
| Sulfonic Acids | 1 | 2006 | 6 | 0.020 |
Why?
|
| Spinal Cord Injuries | 1 | 1993 | 551 | 0.020 |
Why?
|
| Enterotoxins | 1 | 2006 | 40 | 0.020 |
Why?
|
| Diarrhea | 1 | 2006 | 63 | 0.020 |
Why?
|
| Cefotaxime | 1 | 1985 | 7 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2006 | 238 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1993 | 3705 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 1989 | 1054 | 0.020 |
Why?
|
| Digestive System | 1 | 1985 | 35 | 0.020 |
Why?
|
| Infant, Newborn | 4 | 1992 | 2455 | 0.010 |
Why?
|
| Bacteriuria | 1 | 1981 | 7 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2001 | 67 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2001 | 34 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2001 | 37 | 0.010 |
Why?
|
| New Jersey | 1 | 2000 | 8 | 0.010 |
Why?
|
| Connecticut | 1 | 2000 | 13 | 0.010 |
Why?
|
| Amikacin | 1 | 1980 | 13 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1980 | 57 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2000 | 46 | 0.010 |
Why?
|
| Enterobacteriaceae | 1 | 1980 | 29 | 0.010 |
Why?
|
| Clone Cells | 1 | 2000 | 67 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 710 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1977 | 12 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 1977 | 23 | 0.010 |
Why?
|
| Virulence | 1 | 1997 | 51 | 0.010 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 1997 | 7 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1977 | 53 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 4848 | 0.010 |
Why?
|
| Klebsiella | 1 | 1996 | 2 | 0.010 |
Why?
|
| O Antigens | 1 | 1996 | 6 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 2 | 1989 | 84 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1996 | 31 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1977 | 91 | 0.010 |
Why?
|
| Immunotoxins | 1 | 1996 | 23 | 0.010 |
Why?
|
| Models, Organizational | 1 | 1997 | 97 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1996 | 52 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1996 | 90 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 1977 | 168 | 0.010 |
Why?
|
| Novobiocin | 1 | 1993 | 6 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 95 | 0.010 |
Why?
|
| Hospital Units | 1 | 1993 | 21 | 0.010 |
Why?
|
| Rifampin | 1 | 1993 | 45 | 0.010 |
Why?
|
| Adolescent | 2 | 1993 | 8912 | 0.010 |
Why?
|
| Nasal Cavity | 1 | 1993 | 62 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 1992 | 32 | 0.010 |
Why?
|
| Species Specificity | 1 | 1992 | 303 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1993 | 172 | 0.010 |
Why?
|
| Hospitalization | 1 | 1997 | 978 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1991 | 37 | 0.010 |
Why?
|
| Patient Discharge | 1 | 1993 | 294 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 1990 | 7 | 0.010 |
Why?
|
| Hexachlorophene | 1 | 1989 | 1 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1989 | 223 | 0.000 |
Why?
|
| Prevalence | 1 | 1992 | 1619 | 0.000 |
Why?
|
| Teicoplanin | 1 | 1986 | 5 | 0.000 |
Why?
|
| Staphylococcus epidermidis | 1 | 1986 | 12 | 0.000 |
Why?
|
| Glycopeptides | 1 | 1986 | 15 | 0.000 |
Why?
|
| Child | 1 | 1977 | 6405 | 0.000 |
Why?
|
| Lactams | 1 | 1986 | 4 | 0.000 |
Why?
|
| Cost Control | 1 | 1986 | 34 | 0.000 |
Why?
|
| Ampicillin | 1 | 1985 | 17 | 0.000 |
Why?
|
| Hospitals, Community | 1 | 1986 | 64 | 0.000 |
Why?
|
| Premedication | 1 | 1986 | 49 | 0.000 |
Why?
|
| Kinetics | 1 | 1986 | 1047 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1986 | 504 | 0.000 |
Why?
|
| Family Practice | 1 | 1986 | 312 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1985 | 285 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1985 | 7277 | 0.000 |
Why?
|